Blue Dogs Lead Bipartisan Effort to Lower Prescription Drug Costs, Increase Transparency

March 27, 2019 by Dan McCue
Blue Dogs Lead Bipartisan Effort to Lower Prescription Drug Costs, Increase Transparency

The Blue Dog Coalition on Wednesday threw its support behind two bipartisan bills that aim to lower prescription drug costs and increase transparency in the drug pricing system.

The coalition is a House caucus of moderate and fiscally responsible Democrats. The bills they endorsed are the Payment Commission Act and the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act.

Both pieces of legislation are being marked up by the House Energy and Commerce Committee this week.

“In this era of divided government, the only way we can fully address the issues impacting the American people is to find a bipartisan solution that can be implemented into law,” said Rep. Tom O’Halleran, D-Ariz., the Blue Dog co-chair for policy.

“The rising cost of prescription drugs is forcing hardworking families to choose between life-saving medication and other necessities,” he continued. “Congress must act to bring those prices down and increase transparency surrounding drug pricing. Today, the Blue Dogs have come together to address this problem by supporting bipartisan legislation that does just that.”

The Payment Commission Act provides Congress’ independent advisory bodies, the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission, access to certain drug pricing data that will help them formulate recommendations on how to improve the Medicare and Medicaid programs and lower prescription drug prices.

The Act was introduced by O’Halleran and with Representatives Earl L. “Buddy” Carter, R-Ga., Tom Rice, R-S.C., and Jimmy Panetta D-Calif., who believe the legislation will lead to meaningful policy reforms that will ultimately help patients.

Meanwhile, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act, introduced by Blue Dog Co-Chair Representative Kurt Schrader, D-Ore., and Georgia’s Carter, aims to keep drug prices down by increasing competition in the generic drug market.

Currently, drug manufacturers are guaranteed 180 days of market exclusivity when they are the first to file a generic drug application with the FDA.

Intended to reward manufacturers for bringing new low-cost drugs to the market, the current legislative regime includes a flaw that effectively stymies competition.

The 180 days of market exclusivity begin once the first to file manufacturer starts marketing their drug, but even before the first to market begins marketing, all other generic competitors are blocked from coming to market.

This allows manufacturers to “park” the exclusivity before receiving final approval, blocking competition for more than the 180 days intended by the law, the Blue Dog Coalition said.

In these cases, no other generics can come to the market until the first manufacturer receives final approval, begins marketing the drug, and the subsequent 180 days have passed.

The BLOCKING Act would stop such first generic drug “parking” by mandating that if a second generic drug application is blocked from approval solely due to a first generic drug manufacturer parking their exclusivity at the tentative approval stage, the 180 days immediately begins to run, preventing limitless delays.

The legislation mirrors a proposal to “speed development of more affordable generics to spur competition” that was included in the Trump administration’s FY2019 budget proposal.

“Too many patients across this country feel a severe impact from rising drug prices, often on prescriptions they’ve been filling for years,” Representative Schrader said.

“I have long said there is not one silver bullet solution to this crisis, however, we do know that increasing competition on the drug market places a check on manufacturers and keeps costs down,” he continued. “My bill is one such solution that targets and eliminates unnecessary delays in allowing more drugs on the market, ensuring that manufacturers are still incentivized to produce more drugs and that markets continue to see robust competition.”

A+
a-
  • Democrats
  • Drug Prices
  • health
  • legislation
  • In The News

    Health

    Voting

    Health

    Majority of Americans Favor Forgiving Medical Debt, AP-NORC Poll Finds

    NEW YORK (AP) — Janille Williams wants to buy a house someday — but first, he has to pay down... Read More

    NEW YORK (AP) — Janille Williams wants to buy a house someday — but first, he has to pay down tens of thousands of dollars in medical debt. “I was hospitalized for a blood infection for three months more than ten years ago, and the bill... Read More

    Oversight Hearing on Illegal E-Cigarettes Highlights Dire Need for Reform of the FDA

    The Senate deserves credit for holding a recent hearing that underscored the failure of the U.S. Food and Drug Administration’s Center for... Read More

    The Senate deserves credit for holding a recent hearing that underscored the failure of the U.S. Food and Drug Administration’s Center for Tobacco Products to provide clear and fair regulatory pathways for smoke-free tobacco products that provide Americans with less harmful alternatives to combustible cigarettes. This hearing follows... Read More

    June 17, 2024
    by Anna Claire Miller
    Biden Campaign Redoubling Effort to Keep Abortion Rights Front of Mind for Voters

    WASHINGTON — With the second anniversary of the U.S. Supreme Court decision overturning Roe v. Wade fast approaching, the Biden-Harris... Read More

    WASHINGTON — With the second anniversary of the U.S. Supreme Court decision overturning Roe v. Wade fast approaching, the Biden-Harris campaign is organizing volunteers to share what they’ve experienced since that ruling went into effect. Decided on June 24, 2022, Dobbs v. Jackson Women's Health Organization... Read More

    Drug Shortages Keep on Growing. Older, Injectable Medicines Among the Most Vulnerable

    Erin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has... Read More

    Erin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run. Total active shortages hit an all-time high of 323 in this year’s first quarter, according to the University of Utah Drug Information... Read More

    Surgeon General Asks Congress to Require Warning Labels for Social Media, Like Those on Cigarettes

    The U.S. surgeon general has called on Congress to require warning labels on social media platforms similar to those now mandatory... Read More

    The U.S. surgeon general has called on Congress to require warning labels on social media platforms similar to those now mandatory on cigarette boxes. In a Monday opinion piece in the The New York Times, Dr. Vivek Murthy said that social media is a contributing factor in... Read More

    June 17, 2024
    by Jesse Zucker
    How the Ocean Improves Mental and Physical Health

    WASHINGTON — June 20 marks the first day of summer, and there’s nothing like a day by the ocean to... Read More

    WASHINGTON — June 20 marks the first day of summer, and there’s nothing like a day by the ocean to ring it in. In the spirit of the changing season, we’ll discuss how being near or in the ocean can improve mental and physical health. The... Read More

    News From The Well
    scroll top